Regression of Established Hepatocellular Carcinoma Is Induced by Chemoimmunotherapy in An Orthotopic Murine Model

Abstract

These findings indicate that sunitinib inhibits HCC tumor growth directly through the STAT3 pathway and prevents tumor antigen-specific CD8(+) T-cell tolerance, thus defining a synergistic chemoimmunotherapeutic approach for HCC.